MenAfriVac as an Antitetanus Vaccine

Background. The group A meningococcal conjugate vaccine, PsA-TT, uses tetanus toxoid (TT) as a carrier protein (PsA-TT). TT as a carrier protein in other conjugate vaccines is known to be immunogenic and generates a robust anti-TT response. Methods. Clinical studies in Africa assessed whether PsA-TT...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Infect Dis
Asıl Yazarlar: Borrow, Ray, Tang, Yuxiao, Yakubu, Ahmadu, Kulkarni, Prasad S., LaForce, F. Marc
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2015
Konular:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4639489/
https://ncbi.nlm.nih.gov/pubmed/26553690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ512
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller